tiprankstipranks
Crispr Therapeutics price target lowered to $55 from $59 at Barclays
The Fly

Crispr Therapeutics price target lowered to $55 from $59 at Barclays

Barclays lowered the firm’s price target on Crispr Therapeutics (CRSP) to $55 from $59 and keeps an Equal Weight rating on the shares. The company Q3 update highlighted the CTX112 ASH abstract in B-cell malignancies with encouraging initial efficacy, the analyst tells investors in a research note.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App